Pimavanserin (Nuplazid™) for the treatment of Parkinson disease psychosis: A review of the literature

INTRODUCTION: Pimavanserin (Nuplazid™) is an atypical antipsychotic currently indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis. The antipsychotic effects of this new agent are believed to occur via selective inverse agonist activity at serotonin...

Descripción completa

Detalles Bibliográficos
Autores principales: Touma, Katie T. B., Touma, Daniel C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: College of Psychiatric & Neurologic Pharmacists 2018
Materias:
Literature Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007714/
https://www.ncbi.nlm.nih.gov/pubmed/29955528
http://dx.doi.org/10.9740/mhc.2017.09.230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007714/
https://www.ncbi.nlm.nih.gov/pubmed/29955528
http://dx.doi.org/10.9740/mhc.2017.09.230

Ejemplares similares